

Versione 1.2 del 27/04/2021



SIMG

SOCIETÀ ITALIANA DI
MEDICINA GENERALE
E DELLE CURE PRIMARIE

La terapia domiciliare del COVID-19

—

BIBLIOGRAFIA

A cura del Gruppo multidisciplinare collaborativo per il monitoraggio scientifico di COVID-19 (111 Specialisti in Reumatologia, Immunologia Clinica, Malattie Infettive, Medicina Interna) e SIMG.

Bibliografia introduzione.

1. Garg, S; Kim, L; Whitaker, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory confirmed Coronavirus disease 2019-Covid-Net 14 States –March 1-30, 2020- CDC- Morbidity and Mortality Weekly Report
2. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the covid-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. *JAMA* 2020, 323:1545-46
3. Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003, 426: 450-454
4. Hoffmann M , Kleine-Weber H, Schroeder S.et al. SARS-CoV-2 eell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* . 2020 ;181:271-280
5. Zhou R,Li F., Chen F, et al. ,Viral dynamics in asymptomatic patients with COVID-19 . *International Journal of Infectious Diseases* 2020, 96 : 288-290
6. Agra Cavalcante-Silva LH, Madruga Carvalho DC, de Almeida Lima E, et al. Neutrophils and COVID-19: The road so far . *International Immunopharmacology* 2021, 90 : 107233
7. Grant RA, Morales-Nebreda L , Markov NSet al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. *Nature* 2021 ;590:635-641
8. Moore JB, June CH: Cytokine release syndrome in severe COVID-19 -Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease. *Science* 2020, 368: 473-74
9. Gremese E, Ferraccioli ES, Alivernini S. et al. Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. *Europ.J.Clin.Invest.* 2020;50:e13342
10. NIH. COVID-19 Treatment Guidelines. <https://www.covid19treatmentguidelines.nih.gov/> on 3/25/2021
11. Del Valle DM, Kim-Schulze S,Huang H-H et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat. Med.* 2020, 26: 1636-1643.
12. Satarker S, Tom AA, Shaji RA et al. JAK-STAT pathway inhibition and their implications in COVID-19 Therapy. *Postgrad.Med.* 2020 ;1-19. doi: 10.1080/00325481.2020.1855921.

Bibliografia capitolo 1 “FANS-ACIDO ACETILSALICILICO. Quando e perché”.

1. Du F, Jiang P, He S, Song D, Xu F. Antiplatelet therapy for critically ill patients: a pairwise and Bayesian network meta-analysis. *Shock* 2018;49:616–624.
2. Wang L, Li H, Gu X, Wang Z, Liu S, Chen L. Effect of antiplatelet therapy on acute respiratory distress syndrome and mortality in critically ill patients: a meta-analysis. *PLoS One* 2016;11:e0154754.
3. Salah HM, MehtaMeta JL: Analysis of the Effect of Aspirin on Mortality in COVID-19. *Am.J.Cardiol.* 2021 ;142:158-159
4. Merzon E, Green I, Vinker S et al. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. *FEBS J.* 2021, <https://doi.org/10.1111/febs.15784>
5. Chow JH, Khanna AK, Kethireddy S et al. , Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with Coronavirus Disease 2019. *Anesthesia and Analgesia* 2021, 132:930-941
6. Archambault AS, Zaid Y, Rakotoarivelo V et al. Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites. *MedRxiv* doi: <https://doi.org/10.1101/2020.12.04.20242115>;
7. Canzano P, Brambilla M, Porro B, et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. *JACC* : 2021, 6: 202-18
8. Tehrani S, A. Antovic, F. Mobarrez, K. Mageed, P.-E. Lins, U. Adamson, et al., High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes, *Diabetes Care* 2012, 35 : 404–408.
9. Chiang N, E.A. Bermudez, P.M. Ridker, S. Hurwitz, C.N. Serhan, Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial, *Proc. Natl. Acad. Sci. U. S. A.* 2004, 101 : 15178–15183.
10. Abramson SB: Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases. Uptodate www.uptodate.com ©2020
11. Bianconi V, Violi F, Fallarino F, Pignatelli P, Sahebkar A, Pirro M. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? *Drugs.* 2020; 80:1383-1396.
12. Fang L, Karakiulakis G, Roth M. 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* 8:e21.
13. Chen JS, Alfajaro MM, Chow R, et al. Nonsteroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. *J Virol* 95:e00014-21. <https://doi.org/10.1128/JVI.00014-21>.
14. Raaben M, Einerhand AW, Taminiau LJ, et al. . 2007. Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection. *Virology* 4:55.
15. Caso F, Costa L, Ruscitti P, et al.. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? *Autoimmun Rev.* 2020;19:102524.
16. Day M. 2020. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. *BMJ* 368:m1086.
17. Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. *J Clin Invest.* 2020;130:3950-3953
18. Conigliaro P, Triggianese P, Perricone C, et al. .COVID-19: disCOVERing the role of complement system. *Clin Exp Rheumatol.* 2020 ;38:587-591.
19. Ricciotti E, FitzGerald GA.. Prostaglandins and inflammation. *Arterioscler Thromb Vasc Biol* 2011,31:986–1000.
20. Lejal N, Tarus B, Bouguyon E, et al. Structure-based discovery of the novel antiviral properties of naproxen against nucleoprotein of influenza A virus. *Antimicrob Agents Chemother.* 2013;57:2231-42.
21. Zheng W, Fan W, Zhang S, et al. Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export. *Cell Rep.* 2019;27 : 1875-1885.e5.

22. Liu Y, Yao W, Xu J, et al. The anti-inflammatory effects of acetaminophen and N-acetylcysteine through suppression of the NLRP3 inflammasome pathway in LPS-challenged piglet mononuclear phagocytes. *Innate Immun.* 2015;21 :587-97.
23. Graham G.G, Davies MJ , Day R.O et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. *Immunopharmacology* 2013 ;21:201-32
24. Coxib and Traditional NSAID Trialists' Collaboration et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. *Lancet.* 2013;382:769-779.
25. Basille D, Thomsen RW, Madsen M, et al. . Nonsteroidal Antiinflammatory Drug Use and Clinical Outcomes of Community- acquired Pneumonia. *Am J Respir Crit Care Med.* 2018 ;198:128-131.
26. Little P. Non-steroidal anti-inflammatory drugs and covid-19. *BMJ.* 2020;368:m1185.
27. Capuano A, Scavone C, Racagni G, Scaglione F, Italian Society of Pharmacology NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? *Pharmacol. Res.* 2020;157:104849.
28. Pergolizzi JV Jr, Varrassi G, Magnusson P, et al. . COVID-19 and NSAIDS: A narrative Review of knowns and unknowns. *Pain Ther.* 2020 ;9:353-358.
29. Yew WW, Chang KC, Chan DP. Is there a place for anti-inflammatory therapy in COVID-19? *J Thorac Dis.* 2020;12: 7076-7080.
30. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Geneva, Switzerland: World Health Organization; 2020 Jan 28. Available from: <https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>
31. Park J, Lee SH, You SC, Kim J, Yang K. Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19. *Sci Rep.* 2021 ;11:5087.
32. Quispe-Cañari JF, Fidel-Rosales E, Manrique D,. Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. *Saudi Pharm J.* 2021 Jan;29(1):1-11.

Bibliografia capitolo 2 "Anticorpi Monoclonali: Quando e perché".

1. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *N Engl J Med.* 2021;384:229-37.
2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. *N Engl J Med.* 2021;384:238-51.
3. Gottlieb RL, Nirula A; Chen, P et al. Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with Mild to Moderate COVID-19. A randomized clinical trial. *JAMA* 2021;325:632-644. doi:10.1001/jama.2021.0202
4. GAZZETTA UFFICIALE DELLA REPUBBLICA ITALIANA 9-3-2021 Serie generale - n. 58
5. ACTIV-3/TICO LY-CoV555 Study Group : A neutralizing monoclonal antibody for hospitalized patients with Covid-19 . *N Engl J Med* 2021;384:905-14

Bibliografia capitolo 3 "EBPM (Eparine basso peso molecolare): quando e perché".

1. <https://www.aifa.gov.it/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19>.
2. Tang, N.; Bai, H.; Chen, X.; et al . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost.* 2020, 18(5), 1094-1099.
3. Shi, C.; Wang, C.; Wang, H.; et al. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. *Clin Transl Sci.* 2020, 13(6), 1087-1095.

4. Mousavi, S.; Moradi, M.; Khorshidahmad, T.; et al.. *Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. Advances in pharmacological sciences.* 2015, 507151.
5. Thachil, J. *The versatile heparin in COVID-19. J Thromb Haemost.* 2020, 18, 1020-1022.
6. Mattioli, M.; Benfaremo, D.; Mancini, M.; et al. *Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. J Thromb Thrombolysis.* 2020, 13, 1-7.
7. Donno D.R. et al. *How to treat COVID-19 patients at home in the Italian context: An expert opinion. Infect Dis Rep* 2021;13:251-258.
8. Mousavi S et al. . *Adv Pharmacol Sci.* 2015; 2015: 507151.
9. *Coronavirus Disease Treatment Guidelines 2019 (COVID-19)*
<https://www.covid19treatmentguidelines.nih.gov/> on 4/17/2021

Bibliografia capitolo 4 "Colchicina: quando e perché".

1. Gremese E, Ferraccioli ES, Alivernini S. et al. *Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. Europ.J.Clin.Invest.* 2020;50:e13342
2. Gremese E, Ferraccioli G. *The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target. J Intern Med.* 2021;289:420-421.
<https://farmaci.agenziafarmaco.gov.it>
3. Slobodnick A, Shah B, Krasnokutsky S, et al. *Update on colchicine, 2017. Rheumatology* 2018;57:i4i11
4. Y.Y. Leung, L.L. Yao Hui, V.B. Kraus, *Colchicine-Update on mechanisms of action and therapeutic uses, Semin. Arthritis Rheum.* 45 (2015) 341-350
5. Brunetti L, Diawara O, Tsai A et al. *Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J. Clin. Med.* 2020, 9, 2961
6. Hariyanto TI, Halim DA, Jodhinata C et al. *Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Exp Pharmacol Physiol.* 2021;00:1-8.
7. Salah HM, Mehta JI. *Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19. Am J Cardiol* 2021;00:1-2
8. Deftereos SG, Giannopoulos G, Vrachatis DA et al. *Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical. JAMA Netw Open* 2020;3:e2013136
9. Scarsi M, Piantoni S, Colombo E, et al. *Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalized patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis* 2020;79:1286-1289.
10. Sandhu T, Tieng A, Chilimuri S, et al. *A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. Can J Infect Dis Med Microbiol* 2020;2020:8865954.
11. Lopes MI, Bonjorno LP, Giannini MC, et al. *Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv* 2020. 2020.08.06.20169573.
12. Pinzon MA, Arango DC, Betancur JP, et al. *Clinical outcome of patients with COVID-19 pneumonia treated with corticosteroids and colchicine in Colombia. Research Square.* 2020.
13. Tardif J-C, Bouabdallaoui N, L'Allier PL, et al. *Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv* 2021. 2021.01.26.21250494.
14. Alunno A, Najm A, Mariette X et al. *Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Ann Rheum Dis* 2021;0:1-13.
15. Behrens, E.M. and G.A. Koretzky, *Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis Rheumatol,* 2017. 69: p. 1135-1143.

Bibliografia capitolo 5 “Steroidi: quando e perché”.

1. Azkur AK, Akdis M, Azkur D. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy*. 2020; 75:1564-81.
2. Gremese E, Ferraccioli ES, Alivernini S. et al. Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. *Europ.J.Clin.Invest*. 2020;50:e13342
3. Ruan Q, Yang K, Wang W. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020; 46:1294-7. DOI
4. Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; 395:497-506. D
5. Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, Tateda K, Hiramatsu K, Kadota JI. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. *Sci Rep*. 2020 Dec 1;10(1):20935. doi: 10.1038/s41598-020-78054-2. PMID: 33262415; PMCID: PMC7708623.
6. Meduri G.U., Carratu P., Freire A.X. Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS *European Respiratory Journal* Aug 2003, 22 (42 suppl) 57s-64s; DOI: 10.1183/09031936.03.00420903
7. Arabi, Y.M., Chrousos, G.P., Meduri, G.U. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. *Intensive Care Med* 46, 2067-2070 (2020)
8. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE (2009) Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. *Chest* 136:1631-1643
9. Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Meduri GU, Olsen KM, Rochweg B, Rodgers SC, Russell JA, Van den Berghe G (2017) Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a multispecialty task force of the society of critical care medicine (SCCM) and the European society of intensive care medicine (ESICM). *Intensive Care Med* 43:1781-1792
10. Villar J, Ferrando C, Martinez D, Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med*. 2020; 8:267-76.
11. Arabi YM, Mandourah Y, Al-Hameed F et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. *Am J Respir Crit Care Med*. 2018; 197: 757-767
12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. 2020; 395:473-5.
13. Salton F, Confalonieri P, Meduri GU. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. *Open Forum Infect Dis*. 2020;
14. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA*. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023. PMID: 32876694; PMCID: PMC7489434
15. Jeronimo CMP, Farias MEL, Val FFA, for the Metcovid Team. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. *Clin Infect Dis*. 2020; ciaa1177DOI
16. Tomazini BM, Maia IS, Cavalcanti AB. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA*. 2020; 324:1307-16. DOI
17. Angus DC, Derde L, Al-Beidh F. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. *JAMA*. 2020; 324:1317-29. DOI

18. Dequin PF, Heming N, Mezzani F, CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. *JAMA*. 2020; 324:1298–306. DOI
19. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. *N Engl J Med*. 2020; NEJMoa2021436
20. https://www.aifa.gov.it/documents/20142/1123276/Corticosteroidi_06.10.2020.pdf/075c9302-895c-4d7e-11bc-0e2319082ffc
21. World Health Organization (WHO). Corticosteroids for COVID-19. 2020.
22. Ramakrishnan S., Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial . *Lancet Rep.Med*. 2021 [https://doi.org/10.1016/S2213-2600\(21\)00160-0](https://doi.org/10.1016/S2213-2600(21)00160-0)
23. Finney LJ, Glanville N , Hugo Farne H et al., Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. *J.Allergy Clin. Immunol* 2021;147:510-9)
24. Meduri GU, Chrousos GP (2020) General adaptation in critical illness: glucocorticoid receptor-alpha master regulator of homeostatic corrections. *Front Endocrinol* 11:161
25. Jalkanen J, Pettila V, Huttunen T, Hollmen M, Jalkanen S (2020) Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. *Intensive Care Med*

Bibliografia capitolo 6 “LONG-COVID : cosa fare e cosa proporre”.

1. Nalbandian A., Sehgal K, Gupta A et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021; <https://doi.org/10.1038/s41591-021-01283-z>
2. Carfi, A., Bernabei, R., Landi, F. & Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. *JAMA* , 2020: 324, 603–605

Bibliografia tabella

1. INSPIRATION Investigators
Effect of intermediate-dose vs standard-dose prophylactic Anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit The INSPIRATION Randomized Clinical Trial. *JAMA* 2021, DOI:10.1001/jama.2021.4152
2. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. *JACC* 2020, 76: 1815–26